Abstract
The aim of this study was to describe the use of a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol used for treatment of chemotherapy naive T-cell lymphoma patients and to describe the response rate, toxicity and disease-free interval compared historically to CHOP chemotherapy. Retrospective case study of 31 dogs with naïve T-cell lymphoma treated with a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol. Thirty-one dogs with T cell lymphoma were treated. The overall response rate was 97%. Of the 30 dogs that had a response to LOPP chemotherapy, the median disease free interval was 176 days (range 0-1745 days). The median overall survival time for this study group was 323 days (range 51-1758 days). All deaths in this study were attributable to lymphoma. LOPP chemotherapy for T cell lymphoma is well tolerated with a low toxicity profile and an excellent overall response rate. This protocol showed minimal toxicity and comparable disease free interval and survival times for canine high grade T cell lymphoma treated with CHOP.
References
Apr 1, 1991·British Journal of Cancer·B W HancockA M Jelliffe
Jul 1, 1997·Journal of Comparative Pathology·C Fournel-FleuryP Felman
Jul 10, 2002·Veterinary Pathology·C Fournel-FleuryJ P Magnol
Feb 21, 2004·The Veterinary Journal·Frédérique PonceCorinne Fournel-Fleury
Jul 28, 2004·Journal of Comparative Pathology·F A R SueiroJ Vassallo
Jun 21, 2005·Veterinary Immunology and Immunopathology·M J WilkersonA Avery
Jul 5, 2005·Cancer Research·Jaime F ModianoAnne C Avery
Nov 23, 2006·Carcinogenesis·Ryan J HansenM Eileen Dolan
Aug 4, 2009·Journal of Veterinary Internal Medicine·E M BrodskyG S Post
Mar 1, 2006·Veterinary and Comparative Oncology·A K LeBlancJ W Bartges
Mar 17, 2010·Veterinary and Comparative Oncology·D M VailUNKNOWN Veterinary Cooperative Oncology Group
Sep 24, 2010·Veterinary Pathology·V E ValliW Vernau
Feb 10, 2011·Veterinary and Comparative Oncology·R B RebhunC O Rodriguez
Jul 16, 2011·Journal of the American Veterinary Medical Association·Christine E FaheyMonica Clemente
Mar 3, 2012·Veterinary and Comparative Oncology·R C ReganD B Bailey
Feb 28, 2013·Veterinary Pathology·V E ValliF Scott
Mar 28, 2016·The Veterinary Journal·Ingrid H GoodmanAngela E Frimberger
Citations
Jun 27, 2019·Acta Veterinaria Hungarica·Urszula JankowskaRafał Sapierzyński
Aug 1, 2019·The Journal of Small Animal Practice·A TaylorA Lara-Garcia
Mar 17, 2020·Expert Opinion on Drug Discovery·Michael D Lucroy, Mark A Suckow
Sep 6, 2019·Veterinary and Comparative Oncology·Douglas H Thamm, Daniel L Gustafson
Jul 21, 2020·Journal of Feline Medicine and Surgery·Rodrigo S HortaArchivaldo Reche Júnior
Sep 14, 2020·Veterinary and Comparative Oncology·Hiroki YamazakiHideo Akiyoshi
Sep 25, 2020·American Journal of Veterinary Research·Andrea M DedeauxBonnie B Boudreaux
Dec 14, 2018·Acta Veterinaria Scandinavica·Lauge Hjorth MikkelsenSteffen Heegaard
Aug 18, 2018·Veterinary and Comparative Oncology·E MorganA Griffin
Nov 20, 2019·The Journal of Small Animal Practice·J M Dobson
Oct 8, 2020·Veterinary and Comparative Oncology·Zach BohannanSungwon Lim
Mar 13, 2020·Veterinary and Comparative Oncology·Katarzyna PurzyckaAna Lara-Garcia
Mar 2, 2021·Veterinary World·Katarzyna Kliczkowska-KlarowiczRafał A Sapierzyński
Sep 1, 2021·Veterinary and Comparative Oncology·John BlaxillJessica Finlay
Oct 15, 2021·The Journal of Small Animal Practice·J ToddS Nguyen